Stock Events

Stock Events

Synlogic 

€0
0
-€3.63-100% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12MayExpected
Q4 2025
Next
-0.08
0.26
0.59
0.92
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MIN.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, competing in the genetic medicine space similar to Synlogic's approach to synthetic biotics.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing, a direct competitor in the field of genetic and cellular therapies where Synlogic operates.
Editas Medicine
EDIT
Mkt Cap261.32M
Editas Medicine works on gene editing using CRISPR technology, directly competing with Synlogic in the development of novel genetic treatments.
Intellia Therapeutics
NTLA
Mkt Cap1.55B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, making it a competitor in the genetic therapy market.
Beam Therapeutics
BEAM
Mkt Cap2.51B
Beam Therapeutics focuses on precision genetic medicines using base editing, a next-generation CRISPR technology, competing in the same innovative healthcare sector.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, gene editing, and gene regulation, positioning it as a competitor in the genetic treatment market.
Regenxbio
RGNX
Mkt Cap440.26M
REGENXBIO is a leader in the development of AAV-based gene therapies, which places it in competition with companies developing other advanced genetic therapies.
Fate Therapeutics
FATE
Mkt Cap141.84M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the cell therapy space alongside Synlogic's synthetic biotics approach.

About

Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
Show more...
CEO
Ms. Mary Beth Dooley
Employees
1
Country
GB
ISIN
US87166L2097

Listings

STU
DE
MIN.STU
LSE
GB
0A8U.LSE
OTC Link
US
SYBX

0 Comments

Share your thoughts

FAQ

What is Synlogic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Synlogic stocks are traded under the ticker MIN.STU.
Is Synlogic stock price growing?▼
MIN.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Synlogic has showed a +0% increase.
When is the next Synlogic earnings date?▼
Synlogic is going to release the next earnings report on May 12, 2026.
How many employees does Synlogic have?▼
As of April 11, 2026, the company has 1 employees.
When did Synlogic complete a stock split?▼
Synlogic has not had any recent stock splits.
Where is Synlogic headquartered?▼
Synlogic is headquartered in Winchester, GB.